Abstract
Non-muscle invasive bladder cancer (NMIBC) represents approximately 70% of all incident cases of bladder cancer (Large et al.). Consensus guidelines differ on risk definition and in management. A systematic review relating to active surveillance in non-muscle invasive bladder cancer was conducted. This was to identify references relating to bladder cancer and en-bloc resection. The search strategy aimed to identify all references related to bladder cancer AND screening. Search terms used were as follows: (Bladder cancer) AND (low risk) AND (Active Surveillance) . This chapter covers systematic review results.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Gofrit ON, Shapiro A. Active surveillance of low grade bladder tumors. Arch Ital Urol Androl. 2008;80(4):132–5.
Haukaas S, Daehlin L, Maartmann-Moe H, Ulvik NM. The long-term outcome in patients with NMI transitional cell carcinoma of the bladder: a single-institutional experience. BJU Int. 1999;83(9):957–63.
Hernández V, Alvarez M, de la Peña E, Amaruch N, Martín MD, de la Morena JM, Gómez V, Llorente C. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology. 2009;73(6):1306–10.
Hernández V, Llorente C, de la Peña E, Pérez-Fernández E, Guijarro A, Sola I. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol. 2016;34(4):165.e19–23.
Hurle R, Lazzeri M, Vanni E, Lughezzani G, Buffi N, Casale P, Saita A, et al. Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the bias project. J Urol. 2018;199(2):401–6.
Hurle R, Pasini L, Lazzeri M, Colombo P, Buffi N, Lughezzani G, Casale P, Morenghi E, Peschechera R, Zandegiacomo S, Benetti A, Saita A, Cardone P, Guazzoni G. Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the bladder cancer Italian active surveillance (BIAS) project. BJU Int. 2016;118(6):935–9.
Mays N, Pope, C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy. 2005;10(Suppl. 1): 6–20.
Miyake M, Fujimoto K, Hirao Y. Active surveillance for nonmuscle invasive bladder cancer. Investig Clin Urol. 2016;57(Suppl. 1):S4–13.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. BMJ. 2009;339(7716):332–6.
Tiu A, Jenkins LC, Soloway MS. Active surveillance for low-risk bladder cancer. Urol Oncol. 2014;32(1):33.e7–10.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goonewardene, S.S., Persad, R., Motiwala, H., Albala, D. (2020). Active Surveillance in Non-Muscle Invasive Bladder Cancer. In: Management of Non-Muscle Invasive Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28646-0_27
Download citation
DOI: https://doi.org/10.1007/978-3-030-28646-0_27
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-28645-3
Online ISBN: 978-3-030-28646-0
eBook Packages: MedicineMedicine (R0)